| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | RCP; RCP9; RPC9; CGRPRCP; CGRP-RCP |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human CRCP |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇与CRCP(Calcitonin Receptor-Like Receptor Component Protein)抗体相关的文献摘要示例：
---
1. **文献名称**：*CRCP is a novel angiogenic regulator in the tumor microenvironment*
**作者**：Smith A, et al.
**摘要**：本研究利用CRCP特异性抗体，通过免疫组织化学分析发现CRCP在肿瘤血管内皮细胞中高表达，并验证其通过调控VEGF信号通路促进血管生成的作用机制。
---
2. **文献名称**：*Characterization of a monoclonal antibody against human CRCP for functional studies in neuropathic pain*
**作者**：Lee J, Kim H.
**摘要**：作者开发了一种高特异性抗CRCP单克隆抗体，证实其在阻断CGRP受体复合物中的功能，并证明其在抑制慢性疼痛模型中的潜在治疗价值。
---
3. **文献名称**：*CRCP interacts with cytoskeletal proteins: Insights from co-immunoprecipitation assays*
**作者**：Garcia R, et al.
**摘要**：通过CRCP抗体进行免疫共沉淀实验，发现CRCP与α-actinin等细胞骨架蛋白存在相互作用，提示其在细胞迁移和肿瘤转移中的调控作用。
---
**备注**：若CRCP指代其他蛋白(如结肠癌相关蛋白等)，建议补充全称以便提供更精准的文献。实际文献需通过学术数据库(如PubMed)按关键词检索确认。
CRCP (Cripto-1) is a glycosylphosphatidylinositol (GPI)-anchored protein belonging to the epidermal growth factor (EGF)-CFC protein family. Initially identified for its role in embryonic development, CRCP acts as a co-receptor for nodal signaling, a pathway critical for cell differentiation and tissue patterning. It interacts with TGF-β family ligands, facilitating activation of downstream Smad2/3 pathways. Beyond embryogenesis, CRCP is implicated in cancer progression, where its aberrant expression is observed in various malignancies, including breast, colon, and lung cancers. Overexpression of CRCP correlates with enhanced tumor cell proliferation, epithelial-mesenchymal transition (EMT), metastasis, and resistance to apoptosis, making it a potential therapeutic target.
CRCP antibodies are essential tools in both research and diagnostics. They enable detection of CRCP expression in tissues or cell lines via techniques like immunohistochemistry, Western blotting, and flow cytometry. In translational research, these antibodies help elucidate CRCP’s oncogenic mechanisms, including its interplay with signaling pathways like Wnt/β-catenin and PI3K/AKT. Clinically, CRCP antibodies are explored for prognostic applications, as elevated CRCP levels often predict poorer patient outcomes. Additionally, therapeutic monoclonal antibodies targeting CRCP are under investigation to block its oncogenic functions. Despite progress, challenges remain in understanding tissue-specific roles and optimizing antibody specificity. Overall, CRCP antibodies bridge fundamental research and clinical innovation in oncology.
×
